Emergency coronary artery bypass graft surgery in abciximab-treated patients

Annals of Thoracic Surgery

Volumn 69, Issue 1, 2000, Pages 90-95

  Lemmer Jr, John H ^d   Metzdorff, Mark T ^a,b,c   Krause Jr, Albert H ^a,b,c   Martin, M Alan ^a,b,c   Okies, J Edward ^a,b,c   Hill, Jon G ^a,b,c  

^a Northwest Surgical Associates   (United States)

^b Legacy Portland Hospitals   (United States)

^c Southwest Washington Medical Center   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; APROTININ; HEPARIN; PROTAMINE;

ADULT; AGED; ANTICOAGULATION; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; DOSE CALCULATION; EMERGENCY SURGERY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROPHYLAXIS; THROMBOCYTE TRANSFUSION; THROMBOSIS;

AGED; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; BLOOD TRANSFUSION; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY BYPASS; ERYTHROCYTE TRANSFUSION; FEMALE; FORECASTING; HEPARIN; HEPARIN ANTAGONISTS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PLASMA; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET TRANSFUSION; PLATELETPHERESIS; PROTAMINES; RISK ASSESSMENT; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033981028     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(99)01132-7     Document Type: Conference Paper

References (26)

1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. 330:1994;956-961.
2. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.
3. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina the CAPTURE Study . Lancet. 349:1997;1429-1435.
4. Bracey A., Radovancevic R., Vaugh W., Ferguson J., Livesay J. Blood use in emergency coronary artery bypass after receipt of abciximab during angioplasty. Transfusion. 38:1998;685.
5. Boehrer J.D., Kereiakes D.J., Navetta F.I., Califf R.M., Topol E.J. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators evaluation prevention of ischemic complications . Am J Cardiol. 74:1994;1166-1170.
6. Booth J.A., Patel V.B., Balog C., et al. Is bleeding risk increased in patients undergoing urgent coronary bypass surgery following abciximab? [Abstract] Circulation. 98:(Suppl):1998;I845.
7. Gammie J.S., Zenati M., Kormos R.L., et al. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. Ann Thorac Surg. 65:1998;465-469.
8. Juergens C.P., Yeung A.C., Oesterle S.N. Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab. Am J Cardiol. 80:1997;74-75.
9. Alvarez J.M. Emergency coronary bypass grafting for failed percutaneous coronary artery stenting increased costs and platelet transfusion requirements after the use of abciximab . J Thorac Cardiovasc Surg. 115:1998;472-473.
10. Kereiakes D.J. Prophylactic platelet transfusion in abciximab-treated patients requiring emergency coronary bypass surgery. [Letter] Am J Cardiol. 81:1998;373.
11. Ferguson J.J., Kereiakes D.J., Adgey A.A., et al. Safe use of platelet GP IIb/IIIa inhibitors. Am Heart J. 135:1998;S77-S89.
12. Davis R., Whittington R. Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. Drugs. 49:1995;954-983.
13. Lemmer J.H. Jr, Metzdorff M.T., Krause A.H., et al. Aprotinin use in patients with dialysis-dependent renal failure undergoing cardiac operations. J Thorac Cardiovasc Surg. 112:1996;192-194.
14. Reiner A.P. Massive transfusion. Spiess B.D., Counts R.B., Gould S.A. Perioperative transfusion medicine. 1998;353-354 Williams & Wilkins, Baltimore.
15. Yasnoff W.A., Page U.S. Effective use of outcomes data in cardiovascular surgery. Proceedings of the International Society for Optical Engineering. 2307:1994;212-222.
16. Tardiff B.E., Anderson K.M., Cabot C.F., et al. Reduced need for coronary bypass surgery (CABG) after percutaneous intervention in patients treated with abciximab. Circulation. 96:(Suppl):1997;I169.
17. Aguirre F.V., Topol E.J., Ferguson J.J., et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation. 91:1995;2882-2890.
18. Lemmer J.H. Jr. Reporting the results of blood conservation studies the need for uniform and comprehensive methods . Ann Thorac Surg. 58:1994;1305-1306.
19. Ammar T., Scudder L.E., Coller B.S. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation. 95:1997;614-617.
20. Moliterno D.J., Califf R.M., Aguirre F.V., et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol. 75:1995;559-562.
21. Levy J.H., Kelley A. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonists c7E3 Fab on the activated clotting time. [Letter] Circulation. 96:1997;3793-3794.
22. Bennett J.A., Horrow J.C. Activated clotting time one tube or two? J Cardiothorac Vasc Anesth. 10:1996;471-473.
23. Despotis G.J., Joist J.H., Hogue C.W. Jr, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg. 110:1995;46-54.
24. Mascelli M.A., Lance E.T., Damaraju L., Wagner C.L., Weisman H.F., Jordan R.E. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation. 97:1998;1680-1688.
25. Tcheng J.E., Ellis S.G., George B.S., et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 90:1994;1757-1764.
26. Coller B.S. GPIIb/IIIa antagonists pathophysiologic and therapeutic insights from studies of c7E3 Fab . Thromb Haemost. 78:1997;730-735.